DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Glucagon Modulation of Ghrelin Secretion

Information source: Charite University, Berlin, Germany
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy Subjects; Obesity; Diabetes Mellitus, Type 1

Intervention: Glucagon hydrochloride (GlucaGen®) (Drug); NaCl 0.9% (Drug)

Phase: Phase 3

Status: Active, not recruiting

Sponsored by: Charite University, Berlin, Germany

Official(s) and/or principal investigator(s):
Ayman M Arafat, Dr.med., Principal Investigator, Affiliation: Charite Campus Benjamin Franklin


As a counterregulatory hormone for insulin, glucagon plays a critical role in maintaining glucose homeostasis in vivo. It is well known that intramuscular glucagon administration stimulates growth hormone (GH), adrenocorticotropic hormone (ACTH) and cortisol release in humans. Recently, it has been shown that glucagon induces a remarkable decrease in ghrelin levels. The mechanisms underlying this effect are unclear and the role of changes in glucose, insulin, glucagon-like peptide-1 (GLP-1) and catecholamines are widely discussed. The aim of the present study is to further evaluate the effect of glucagon on ghrelin secretion and the possible role of the above mentioned factors in mediating this effect.

Clinical Details

Official title: The Mechanisms Underlying the Glucagon-Induced Suppression of Ghrelin Secretion

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science

Primary outcome: Changes in satiety scale, total and acylated ghrelin concentrations.

Secondary outcome: Changes in glucose, insulin and NEFA concentrations.


Minimum age: 18 Years. Maximum age: 60 Years. Gender(s): Both.


Inclusion Criteria:

- Subjects > 18 and < 60 years old.

- Patients with diabetes type 1 should fulfill the following criteria:

- ICT Insulin therapy was necessary within the first 3 months after diagnosis;

- HbA1c-Wert < 7%.

Exclusion Criteria:

- Diabetes type 1 or 2 (for the healthy group).

- Biochemical evidence of impaired hepatic or renal function.

- History of cardiovascular disease.

- Uncontrolled hypertension.

- Current inflammatory, malignant or psychiatric disease.

- Pregnancy

Locations and Contacts

Charite Campus Benjamin Franklin, Berlin 12200, Germany
Additional Information

Department website

Related publications:

Arafat AM, Perschel FH, Otto B, Weickert MO, Rochlitz H, Schöfl C, Spranger J, Möhlig M, Pfeiffer AF. Glucagon suppression of ghrelin secretion is exerted at hypothalamus-pituitary level. J Clin Endocrinol Metab. 2006 Sep;91(9):3528-33. Epub 2006 Jun 20.

Starting date: June 2006
Last updated: June 29, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017